Benzinga··PrnewswireIceCure's ProSense® Posts 89% Kidney Cancer Recurrence-Free Rate at ECIO 2026
IceCure Medical reported 89.4% recurrence-free rate for kidney cancer using ProSense® cryoablation at ECIO 2026, with 100% cosmetic outcomes in breast applications.
ICCMbreast cancerclinical trial